Published on Mon Aug 09 2021

A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.

Federico Martinón-Torres, Isabelle Bertrand-Gerentes, Philipp Oster

quadrivalent meningococcal conjugate vaccines have been effective in preventing invasive meningitis. Data on their efficacy and safety in adults ≥56 years of age are lacking. MenACYW-TT was approved in 2020 for use in individuals ≥12 months of age as a single dose

1
3
12
Abstract

Although quadrivalent meningococcal conjugate vaccines have been effective in preventing invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y across age groups from infants to adults, data on their efficacy and safety in adults ≥56 years of age are lacking. Moreover, multiple available quadrivalent conjugate vaccines require reconstitution prior to administration, introducing the potential for error. A novel quadrivalent meningococcal conjugate vaccine, MenACYW-TT (MenQuadfi®) was approved in 2020 for use in individuals ≥12 months of age as a single dose in the European Union and some other countries and in individuals ≥2 years of age in the United States.